Form D · Biotechnology

Prelude Therapeutics Inc

Wilmington, DE · CIK 0001678660

Offering snapshot reported Aug 28, 2020 · SEC filing

Reported sold
$50M
Offering amount: $50M
Investors reported
7
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 21, 2020
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 28, 2020Initial$49,999,969No comparison7SEC filing
Jun 17, 2019Initial$29,999,999No comparison6SEC filing
Aug 17, 2018Amendment$29,999,998$17,999,998vs Oct 20, 20177SEC filing
Oct 20, 2017Initial$12,000,000No comparison7SEC filing
Jul 11, 2016Initial$5,000,000No comparison8SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-374395

Source: Form D, filed Aug 28, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
David Bonita Director
Andrew Combs Executive
Mardi C. Dier Director
Paul Friedman Director
Juan Luengo Executive
David Mauro Executive
Deborah Morosini Executive
Kelvin Neu Director
Christopher Pierce Executive
Brian Piper Executive
Victor Sandor Director
Peggy Scherle Executive
Krishna Vaddi Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
200 Powder Mill Road Experimental Station E400/3213
Wilmington, DE, 19803